GSK's new pain category

GSK has announced it has developed a new pain category approach it intends to showcase at APP2018 conference on the Gold Coast. The company says it is looking forward to partnering with Australian pharmacists to pioneer their new in-store initiative aiming to “drive category growth and deliver better patient outcomes”.

Australian pharmacy continues to face challenging environmental moves resulting in a decline in total pharmacy value and increased uncertainty due to structural and regulatory change, GSK noted.  However, there are also trends such as an ageing population and the self-care movement creating opportunities for industry growth in pharmacy, which category and product innovation can help make a reality.

The opportunity GSK is presenting is based on an “innovative new approach” to the pain category fixture founded on research and insights gathered from a wide set of locally commissioned qualitative and quantitative sources, as well as the Global Pain Index. The new approach could potentially drive a 10% uplift in the pain category for pharmacies in the next five years, GSK said in its pre-APP Conference release.

GSK Consumer Healthcare head of pharmacy Michael King said, “We are committed to working with pharmacists to innovate in our industry and, ultimately, deliver better health outcomes for consumers as well as supporting business growth. “Our new pain category solution is a science led global first that we have been piloting in Australia.

“We’re excited to be able to showcase that at APP 2018 and start working with more pharmacists to shape the future of Australian pharmacy.” The new pain category can be seen at APP stand 144-149.

To learn more aboub pain  and pain managment, view the QCPP education module 'Voltaren - NOn-prescription Pain Relief Range' below.

Source: pharmacydaily.com.au, Friday 27 April 2018